Role of oral teriflunomide in the management of multiple sclerosis

Tanasescu, Radu and Evangelou, Nikos and Constantinescu, Cris S. (2013) Role of oral teriflunomide in the management of multiple sclerosis. Neuropsychiatric Disease and Treatment, 9 . pp. 539-553. ISSN 1176-6328

[img] PDF - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
Download (424kB)

Abstract

The landscape of the treatment of relapsing–remitting multiple sclerosis is changing fast. Several oral treatments have shown benefit and generate much interest because of the convenience of their administration. Two oral compounds, fingolimod and teriflunomide, have been approved in relapsing–remitting multiple sclerosis, while others have completed Phase III trials and are awaiting review for registration. Teriflunomide is a pyrimidine synthesis inhibitor with selective immunomodulatory and immunosuppressive properties that have shown consistent efficacy in clinical trials, and a good safety profile. This paper provides an overview of the mechanisms of action and efficacy and safety results from clinical trials with this drug. The role of teriflunomide in the treatment of relapsing–remitting multiple sclerosis is discussed.

Item Type: Article
Schools/Departments: University of Nottingham UK Campus > Faculty of Medicine and Health Sciences > School of Medicine
Identification Number: https://doi.org/10.2147/NDT.S31248
Depositing User: Wahid, Ms. Haleema
Date Deposited: 28 Apr 2014 11:32
Last Modified: 16 Sep 2016 04:58
URI: http://eprints.nottingham.ac.uk/id/eprint/3057

Actions (Archive Staff Only)

Edit View Edit View